Examples
|
| Aricept | donepezil | |
| Razadyne | galantamine | |
| Exelon | rivastigmine | |
How It Works
Cholinesterase inhibitors increase the
level of a brain chemical called acetylcholine. People with
Alzheimer's disease and related conditions have
decreased brain levels of this neurotransmitter. Increasing the amount of
acetylcholine appears to slow mental decline in people with Alzheimer's
disease.
These medicines help the brain cells work better but do
not stop or reverse the destruction of brain cells and loss of acetylcholine
that occur in Alzheimer's disease. They do not prevent the disease from getting
worse but may slow the progression of symptoms.
How Well It Works
Cholinesterase inhibitors may
produce small improvements in memory and general ability to function.1 For example, the person may be able to remember friends'
names better and be able to dress himself or herself with less
difficulty.
- Studies have shown that people with mild to
moderately severe Alzheimer's who took donepezil scored somewhat higher in
their doctors' evaluations of their mental and functional status than those who
did not take the drug.1
- Studies show that
rivastigmine has beneficial effects similar to donepezil. Rivastigmine has more
side effects, including nausea and possible weight loss. Because of the side
effects, more people stop treatment with rivastigmine.1
- Galantamine is available in the United States. It
may improve memory and thinking abilities.
- Improvement with
cholinesterase inhibitors usually is minimal. The person's mental status does
not stabilize, but the rate of decline may be somewhat slower than it would be
without the medicine.
- Improvement in symptoms may be more likely at
higher doses, but higher doses also may cause more side
effects.
- Doctors don't know for sure that cholinesterase inhibitors
help with behavior problems in people who have Alzheimer's disease.2 Some studies show that these medicines do help, which can
mean less burden on caregivers.3 But other studies
show that these medicines do not help.4, 5
- Cholinesterase inhibitors may have some use in other dementias,
such as dementia with Lewy bodies and multi-infarct dementia.
Cholinesterase inhibitors do not help everyone who has
Alzheimer's disease. It is believed that as the disease progresses, the
medicine eventually may stop working.
The various cholinesterase
inhibitors have similar effects on memory and cognitive function, so the choice
between medicines may be based on side effects, dosing schedules and ease of
use, individual response to a particular medicine, or other factors.
Side Effects
In general, most people seem to
tolerate cholinesterase inhibitors very well. The most common side effects
are:
- Nausea.
- Diarrhea.
- Vomiting.
- Indigestion.
- Abdominal
pain.
- Loss of appetite and weight loss.
Less common side effects include insomnia, fatigue, and
muscle cramps. Side effects tend to be mild and usually go away within a few
weeks after treatment with the medicine is started.
See Drug
Reference for a full list of side effects. (Drug Reference is not available in
all systems.)
What To Think About
Cholinesterase inhibitors do not
work for everyone who has Alzheimer's disease, but they are helpful for some
people. They may be a reasonable option for those who understand the risks and
costs and feel the possible benefits are worth it.
Most studies of
cholinesterase inhibitors for people with Alzheimer's disease found that the
benefits of taking these medicines are small.6, 4
Side effects seem to be milder and occur less
often with donepezil or galantamine than with rivastigmine.
Experts agree that reducing problems with memory loss may help people
with Alzheimer's disease live better. In some cases, reducing these problems
may help people live more independently for a longer period of time.
Rivastigmine (Exelon) can now be given through a skin patch. Skin
patches release medicine into the blood at a steady level and may reduce side
effects. And it's easier for caregivers to make sure a person is taking the
medicine properly when the person uses a skin patch.
Complete the new medication information form (PDF)
(What is a PDF document?)
to help you understand this medication.
References
Citations
Warner J, et al. (2008). Dementia, search date
February 2006. Online version of BMJ Clinical Evidence.
Also available online: http://clinicalevidence.com.
Sink KM, et al. (2005). Pharmacological treatment of
neuropsychiatric symptoms of dementia: A review of the evidence.
JAMA, 293(5): 596-608.
Trinh NH, et al. (2003). Efficacy of cholinesterase
inhibitors in the treatment of neuropsychiatric symptoms and functional
impairment in Alzheimer disease: A meta-analysis. JAMA,
289(2): 210-216.
Raina P, et al. (2008). Effectiveness of
cholinesterase inhibitors and memantine for treating dementia: Evidence review
for a clinical practice guideline. Annals of Internal Medicine, 148(5): 379-397.
Howard RJ, et al. (2007). Donepezil for the treatment
of agitation in Alzheimer's disease. New England Journal of Medicine, 357(14): 1382-1392.
Kaduszkiewicz H, et al. (2005). Cholinesterase
inhibitors for patients with Alzheimer's disease: Systematic review of
randomised clinical trials. BMJ, 331(7512): 321-327.
Credits
| Author | Monica Rhodes |
| Editor | Kathleen M. Ariss, MS |
| Associate Editor | Pat Truman, MATC |
| Primary Medical Reviewer | Anne C. Poinier, MD - Internal Medicine |
| Specialist Medical Reviewer | Peter J. Whitehouse, MD - Neurology |
| Last Updated | November 10, 2008 |
Warner J, et al. (2008). Dementia, search date
February 2006. Online version of BMJ Clinical Evidence.
Also available online: http://clinicalevidence.com.
Sink KM, et al. (2005). Pharmacological treatment of
neuropsychiatric symptoms of dementia: A review of the evidence.
JAMA, 293(5): 596-608.
Trinh NH, et al. (2003). Efficacy of cholinesterase
inhibitors in the treatment of neuropsychiatric symptoms and functional
impairment in Alzheimer disease: A meta-analysis. JAMA,
289(2): 210-216.
Raina P, et al. (2008). Effectiveness of
cholinesterase inhibitors and memantine for treating dementia: Evidence review
for a clinical practice guideline. Annals of Internal Medicine, 148(5): 379-397.
Howard RJ, et al. (2007). Donepezil for the treatment
of agitation in Alzheimer's disease. New England Journal of Medicine, 357(14): 1382-1392.
Kaduszkiewicz H, et al. (2005). Cholinesterase
inhibitors for patients with Alzheimer's disease: Systematic review of
randomised clinical trials. BMJ, 331(7512): 321-327.